Thyroseq v3 results

Author: utnm

August undefined, 2024

Webb8 okt. 2024 · FNA diagnoses were correlated with ThyroSeq v3 results and follow-up histopathology. Results In total, 415 cases (AUS/FLUS, n = 251; FN/SFN, n = 164) were … WebbResults: We included 8 Bethesda category III nodules that underwent ThyroSeq® and 8 that underwent diagnostic surgery. Of those submitted for ThyroSeq®, 4 were positive …

Single Institution Experience with Afirma and Thyroseq Testing in ...

Webb1 apr. 2024 · The negative predictive values for v2 and v3 were 92% and 100%, respectively. Conclusions: The PPV of an HRM result on ThyroSeq v3 was low for malignancy or … Webb27 apr. 2024 · The negative predictive values for v2 and v3 were 92% and 100%, respectively. Conclusions The PPV of an HRM result on ThyroSeq v3 was low for … jeds auto

Analytical performance of the ThyroSeq v3 genomic

Webb4 apr. 2024 · National Center for Biotechnology Information WebbThe latest version of this test, ThyroSeq v3, is based on NGS of DNA and RNA. This test detects 4 types of alterations; mutations, gene fusions, expression alterations, and copy number alterations. This test analyzes 112 genes, providing information on more than 12,000 mutation hotspots and more than 120 gene fusion types. WebbThyroSeq ® v3 is also based on next-generation sequencing of DNA and RNA. However, it is expanded to analyze 112 genes, providing information on >12,000 mutation hotspots and >150 gene fusion types (Nikiforova … jed satow

Hürthle cell lesions on thyroid fine needle aspiration cytology ...

Webb30 okt. 2024 · The detailed molecular results from ThyroSeq v3 contribute information toward determining the indication for surgery, the extent of surgery, and the prediction of … WebbThyroSeq can help with diagnosis of your nodule . Approximately 20% of fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate by cytology, making diagnosis of the nodule unclear. ThyroSeq provides … jed savardWebb17 apr. 2024 · The multigene genomic classifier ThyroSeq V3 has proven to be an effective triage modality in the management of indeterminate thyroid nodules. ... Results. Of the … jed savager

"WebbIndependent study of ThyroSeq v3from the University of Pennsylvania of 415 Bethesda III-IV thyroid nodules Results: ThyroSeq benign call rate was 71% ThyroSeq had a high NPV … " - Thyroseq v3 results

Thyroseq v3 results

Webb9 nov. 2024 · 共有257个（90%）结节（154个为Bethesda III类，93个为Bethesda IV类，10个为Bethesda V类）经过GC分析得到结果，其中61%为阴性，39%为阳性。综合Bethesda III和IV类结节来看，该检测方法的敏感性为94%（95% CI, 86%-98%），特异性为82%（95% CI, 75%-87%）。因为甲状腺癌/NIFTP的患病率为28%，阴性预测值（NPV） … WebbFor the remaining cases, the indeterminate diagnoses were correlated with molecular and histologic results. Results: Among the 224 indeterminate cases (except those deemed …

Did you know?

WebbThe results of the ThyroSeq® test are reported in a user-friendly format that contains: Report Summary with an assessed probability of cancer in the patient's nodule and suggested potential clinical management. Result Interpretation section in which test … WebbThis study aimed to examine whether concurrent mutations with a TERT promoter mutation are associated with a greater likelihood of more aggressive disease than a TERT promoter mutation alone. The medical records of 1477 patients who underwent thyroid surgery at two tertiary hospitals between 2024 and 2024 were reviewed. Twenty-four …

Webb1 mars 2024 · These results increased the probability of cancer or NIFTP to 50%-60% and the ThyroSeq v3 result was reported as “positive.” Due to developing clinical concern … Webb13 maj 2024 · Thyroseq v3 showed the best overall performance (AUC 0.95; 95% confidence interval: 0.93-0.97), followed by Afirma GSC (AUC 0.90; 0.87-0.92) and …

Webb17 apr. 2024 · ThyroSeq V3 testing at our institution was implemented April 1, 2024. Over a 17-month period ... Results. Of the 35 nodules, 17 (49%) were positive and 18 (51%) were … Webb3 apr. 2024 · Among the mutations, RAS mutations were the most common positive results (34) Chen et al. published their Canadian experience with ThyroSeq v3 in a series of 50 …

WebbOf these biopsies, 59% of nodules had a negative Thyroseq v3 result (i.e., no high-risk mutations). Five (3%) samples were reported as negative that turned out to be low-risk …

Webb8 okt. 2024 · The ThyroSeq v3 genomic classifier is a commercial molecular test that examines a wide spectrum of genomic alterations in a thyroid fine‐needle aspiration … jedsa ortuellaWebb8 sep. 2024 · A previous test panel (ThyroSeq v2 next-generation sequencing [CBLPath]) included 14 genes and 42 gene fusions, and displayed a diagnostic sensitivity of 70% to … laguardia parking long termWebb11 juni 2024 · Results. Most patients were female (78.0%), with a median age of 56 years (range 30-84). ... ThyroSeq v3 is a useful stratification tool for those patients with … jed's auto repair